Schouten O, Lever T M, Welten G M J M, Winkel T A, Dols L F C, Bax J J, van Domburg R T, Verhagen H J M, Poldermans D
Department of Vascular Surgery, Erasmus MC, Rotterdam, The Netherlands.
Eur J Vasc Endovasc Surg. 2008 Dec;36(6):646-52. doi: 10.1016/j.ejvs.2008.09.008. Epub 2008 Oct 14.
To assess long-term outcome of patients at high cardiac risk undergoing endovascular or open AAA repair.
Patients undergoing open or endovascular infrarenal AAA repair with >or=3 cardiac risk factors and preoperative cardiac stress testing (DSE) at 2 university hospitals were studied. Main outcome was cardiac event free and overall survival. Multivariate Cox regression analysis was used to evaluate the influence of type of AAA repair on long-term outcome.
In 124 patients (55 endovascular, 69 open) the number and type of cardiac risk factors, medication use and DSE results were similar in both groups. In multivariable analysis, adjusting for cardiac risk factors, stress test results, medication use, and propensity score endovascular repair was associated with improved cardiac event free survival (HR 0.54; 95% CI 0.30-0.98) but not with an overall survival benefit (HR 0.73; 95% CI 0.37-1.46). Importantly, statin therapy was associated with both improved overall survival (HR 0.42; 95% CI 0.21-0.83) and cardiac event free survival (HR 0.45; 95% CI 0.23-0.86).
The perioperative cardiac benefit of endovascular AAA repair in high cardiac risk patients is sustained during long-term follow-up provided patients are on optimal medical therapy but it is not associated with improved overall long-term survival.
评估具有高心脏风险的患者接受血管内或开放性腹主动脉瘤修复术的长期预后。
对两所大学医院中接受开放性或血管内肾下腹主动脉瘤修复术且具有≥3个心脏风险因素并进行术前心脏负荷试验(DSE)的患者进行研究。主要结局为无心脏事件生存和总生存。采用多变量Cox回归分析评估腹主动脉瘤修复类型对长期预后的影响。
124例患者(55例行血管内修复,69例行开放性修复)中,两组的心脏风险因素数量和类型、药物使用情况及DSE结果相似。在多变量分析中,校正心脏风险因素、负荷试验结果、药物使用情况和倾向评分后,血管内修复与改善无心脏事件生存相关(风险比0.54;95%可信区间0.30 - 0.98),但与总生存获益无关(风险比0.73;95%可信区间0.37 - 1.46)。重要的是,他汀类药物治疗与改善总生存(风险比0.42;95%可信区间0.21 - 0.83)和无心脏事件生存(风险比0.45;95%可信区间0.23 - 0.86)均相关。
对于高心脏风险患者,血管内腹主动脉瘤修复术的围手术期心脏获益在长期随访中持续存在,前提是患者接受最佳药物治疗,但这与改善总体长期生存无关。